ABCC4 and cystic fibrosis: It has been previously demonstrated that pharmacological inhibition of ABCC4 by MK-571, in combination with VX-770, was able to improve CFTR activity in primary nasal epithelial cells from CF patients heterozygous for the G551D-variant14.